Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients

W. Ray Kim; Thomas Berg; Tarik Asselah; Robert Flisiak; Scott Fung; Stuart C. Gordon; Harry L A Janssen; Pietro Lampertico; Daryl Lau; Jeffrey D. Bornstein; Raul E Aguilar Schall; Phillip Dinh; Leland J. Yee; Eduardo B. Martins; Seng Gee Lim; Rohit Loomba; Jörg Petersen; Maria Buti; Patrick Marcellin

doi:10.1016/j.jhep.2015.11.012

Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients

W. Ray Kim, Thomas Berg, Tarik Asselah, Robert Flisiak, Scott Fung, Stuart C. Gordon, Harry L A Janssen, Pietro Lampertico, Daryl Lau, Jeffrey D. Bornstein, Raul E Aguilar Schall, Phillip Dinh, Leland J. Yee, Eduardo B. Martins, Seng Gee Lim, Rohit Loomba, Jörg Petersen, Maria Buti, Patrick Marcellin

Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico

Research output: Contribution to journal › Article › peer-review

Abstract

Background & Aims: While the gold standard in the assessment of liver fibrosis remains liver biopsy, non-invasive methods have been increasingly used for chronic hepatitis B (CHB). This study aimed to evaluate the performance of two commonly used non-invasive scoring systems (aspartate aminotransferase-to-platelet ratio index (APRI) and fibrosis index based on four factors (FIB-4)) to predict fibrosis stage in CHB patients. Materials and methods: Demographic, histologic and clinical laboratory data from two trials investigating tenofovir disoproxil fumarate in CHB were analyzed. Predicted fibrosis stage, based on established scales and cut-off values for APRI and FIB-4 scores, was compared with Ishak scores obtained from liver biopsy at baseline and at 240. week follow-up. Results: In the 575 patients with a baseline liver biopsy, APRI and FIB-4 scores correlated with Ishak stage (p

Original language	English
Journal	Journal of Hepatology
DOIs	https://doi.org/10.1016/j.jhep.2015.11.012
Publication status	Accepted/In press - May 21 2015

Keywords

APRI
Chronic hepatitis B
FIB-4
Fibrosis

ASJC Scopus subject areas

Hepatology

Access to Document

10.1016/j.jhep.2015.11.012

Cite this

Ray Kim, W., Berg, T., Asselah, T., Flisiak, R., Fung, S., Gordon, S. C., Janssen, H. L. A., Lampertico, P., Lau, D., Bornstein, J. D., Schall, R. E. A., Dinh, P., Yee, L. J., Martins, E. B., Lim, S. G., Loomba, R., Petersen, J., Buti, M., & Marcellin, P. (Accepted/In press). Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2015.11.012

Ray Kim, W, Berg, T, Asselah, T, Flisiak, R, Fung, S, Gordon, SC, Janssen, HLA, Lampertico, P, Lau, D, Bornstein, JD, Schall, REA, Dinh, P, Yee, LJ, Martins, EB, Lim, SG, Loomba, R, Petersen, J, Buti, M & Marcellin, P 2015, 'Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients', Journal of Hepatology. https://doi.org/10.1016/j.jhep.2015.11.012

@article{757a708385224015b08f079079a9812e,

title = "Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients",

abstract = "Background & Aims: While the gold standard in the assessment of liver fibrosis remains liver biopsy, non-invasive methods have been increasingly used for chronic hepatitis B (CHB). This study aimed to evaluate the performance of two commonly used non-invasive scoring systems (aspartate aminotransferase-to-platelet ratio index (APRI) and fibrosis index based on four factors (FIB-4)) to predict fibrosis stage in CHB patients. Materials and methods: Demographic, histologic and clinical laboratory data from two trials investigating tenofovir disoproxil fumarate in CHB were analyzed. Predicted fibrosis stage, based on established scales and cut-off values for APRI and FIB-4 scores, was compared with Ishak scores obtained from liver biopsy at baseline and at 240. week follow-up. Results: In the 575 patients with a baseline liver biopsy, APRI and FIB-4 scores correlated with Ishak stage (p ",

keywords = "APRI, Chronic hepatitis B, FIB-4, Fibrosis",

author = "{Ray Kim}, W. and Thomas Berg and Tarik Asselah and Robert Flisiak and Scott Fung and Gordon, {Stuart C.} and Janssen, {Harry L A} and Pietro Lampertico and Daryl Lau and Bornstein, {Jeffrey D.} and Schall, {Raul E Aguilar} and Phillip Dinh and Yee, {Leland J.} and Martins, {Eduardo B.} and Lim, {Seng Gee} and Rohit Loomba and J{\"o}rg Petersen and Maria Buti and Patrick Marcellin",

year = "2015",

month = may,

day = "21",

doi = "10.1016/j.jhep.2015.11.012",

language = "English",

journal = "Journal of Hepatology",

issn = "0168-8278",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients

AU - Ray Kim, W.

AU - Berg, Thomas

AU - Asselah, Tarik

AU - Flisiak, Robert

AU - Fung, Scott

AU - Gordon, Stuart C.

AU - Janssen, Harry L A

AU - Lampertico, Pietro

AU - Lau, Daryl

AU - Bornstein, Jeffrey D.

AU - Schall, Raul E Aguilar

AU - Dinh, Phillip

AU - Yee, Leland J.

AU - Martins, Eduardo B.

AU - Lim, Seng Gee

AU - Loomba, Rohit

AU - Petersen, Jörg

AU - Buti, Maria

AU - Marcellin, Patrick

PY - 2015/5/21

Y1 - 2015/5/21

N2 - Background & Aims: While the gold standard in the assessment of liver fibrosis remains liver biopsy, non-invasive methods have been increasingly used for chronic hepatitis B (CHB). This study aimed to evaluate the performance of two commonly used non-invasive scoring systems (aspartate aminotransferase-to-platelet ratio index (APRI) and fibrosis index based on four factors (FIB-4)) to predict fibrosis stage in CHB patients. Materials and methods: Demographic, histologic and clinical laboratory data from two trials investigating tenofovir disoproxil fumarate in CHB were analyzed. Predicted fibrosis stage, based on established scales and cut-off values for APRI and FIB-4 scores, was compared with Ishak scores obtained from liver biopsy at baseline and at 240. week follow-up. Results: In the 575 patients with a baseline liver biopsy, APRI and FIB-4 scores correlated with Ishak stage (p

AB - Background & Aims: While the gold standard in the assessment of liver fibrosis remains liver biopsy, non-invasive methods have been increasingly used for chronic hepatitis B (CHB). This study aimed to evaluate the performance of two commonly used non-invasive scoring systems (aspartate aminotransferase-to-platelet ratio index (APRI) and fibrosis index based on four factors (FIB-4)) to predict fibrosis stage in CHB patients. Materials and methods: Demographic, histologic and clinical laboratory data from two trials investigating tenofovir disoproxil fumarate in CHB were analyzed. Predicted fibrosis stage, based on established scales and cut-off values for APRI and FIB-4 scores, was compared with Ishak scores obtained from liver biopsy at baseline and at 240. week follow-up. Results: In the 575 patients with a baseline liver biopsy, APRI and FIB-4 scores correlated with Ishak stage (p

KW - APRI

KW - Chronic hepatitis B

KW - FIB-4

KW - Fibrosis

UR - http://www.scopus.com/inward/record.url?scp=84957066037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957066037&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2015.11.012

DO - 10.1016/j.jhep.2015.11.012

M3 - Article

AN - SCOPUS:84957066037

SN - 0168-8278

JO - Journal of Hepatology

JF - Journal of Hepatology

ER -

Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this